Sage Therapeutics

Youtube Subscribe

Open: 26.14 Close: 25.41 Change: -0.73

The 6 top things that an AI found about Sage Therapeutics... they will surprise you

The game is changing. There is a new strategy to evaluate Sage Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sage Therapeutics are: Therapeutics, Sage, company, SAGE, report, Q4, Buy, …

Concept Map

Semantic Network

Stock Summary

25 out of the 910 hedge funds surveyed by Insider Monkey had bought and owned Sage Therapeutics, Inc. The company has a 52 week low of $22.51 and a high of $59.99. Tower Research Capital.

Today's Summary

Cowen analyst Ritu Baral maintained a Buy rating on SAGE Therapeutics ( SAGE – Research Report ) yesterday and set a price target of $30.00. Cowen: Pursing early demand signals

Today's News

Cowen analyst Ritu Baral maintained a Buy rating on SAGE Therapeutics ( SAGE – Research Report ) yesterday and set a price target of $30.00. Buy rating due to a combination of factors, including promising early demand signals. Sage Therapeutics receives FDA Orphan Drug Designation for SAGE-718 in the treatment of Huntingtons disease. Sage Therapies to present at Upcoming September Investor Conferences. Sage Therapeutics Inc (SAGE) Reports Fourth Quarter and Full Year 2023 Financial Results. Company reports significant progress in its pipeline and business operations. Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference. Companys Q1 earnings are confirmed for Tuesday, April 30, 2024. Company is in the Health Care sector and Biotechnology industry. Sage Therapeutics shares are trading higher after the company reported better-than-expected Q4 revenue results. The company announced the retirement of Kevin Starr from the companys board of directors. Sage Therapeutics is scheduled to announce Q4 earnings results on Wednesday, February 14th, before market open. The company said its new medicine, the first oral treatment for postpartum depression, is off to an encouraging start. Sage Therapeutics reported initial sales of ZURZUVAE at $824,000 and a milestone moomoo AI. Q4 revenue of $77.97M beats by $16.99M.

Stock Profile

" Recent study raises questions about safety of Sage Therapeutics Zurzuvae (zuranolone) for postpartum depression, charging that the drug exerts risks similar to those seen with benzodiazepines. 25 out of the 910 hedge funds surveyed by Insider Monkey had bought and owned Sage Therapeutics, Inc. (NASDAQ: SAGE) As of September 2023, 25 of the 10,000 hedge fund investors surveyed had bought the company. The company has a 52 week low of $22.51 and a high of $59.99. Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Tower Research Capital LLC TRC increased its holdings in Sage Theraputics by 74.0% during the third quarter. Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. The firm encourages investors to contact the firm. The firm is investigating potential claims against Sage Theraputics. Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. Company size 501-1,000 employees is expected to be around 690."

Keywords

How much time have you spent trying to decide whether investing in Sage Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sage Therapeutics are: Therapeutics, Sage, company, SAGE, report, Q4, Buy, and the most common words in the summary are: sage, therapeutic, stock, news, job, top, dividend, . One of the sentences in the summary was: Cowen: Pursing early demand signals. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #sage #therapeutic #stock #news #job #top #dividend.

Read more →

Youtube Subscribe

---